Virtual Library
Start Your Search
J. Zhang
Author of
-
+
P3.02 - Biology/Pathology (ID 620)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.02-026 - The Study of ROS1 Rearrangement in Advanced Primary Non-Small Cell Lung Cancer and Associated Metastatic Lesions (ID 8281)
09:30 - 09:30 | Author(s): J. Zhang
- Abstract
Background:
ROS1 rearrangement in non-small cell lung cancer(NSCLC) patients has recently been identified as a driver gene and benefited from crizotinib treatment. However, no data are available for ROS1 rearrangement NSCLC about relationship between primary and metastatic patients. The aim of this study is to examine the positive rate of ROS1 rearrangement in primary and metastatic NSCLC, and to investigate their relationships.
Method:
From January 2013 to May 2015, 384 cases of primary NSCLC consisting of 246 cases of matched metastatic tumors and 47 cases of normal lung specimens as the control group were collected in multicenter. The positive rate of ROS1 rearrangement among NSCLC population was figured out, thus the consistency of ROS1 rearrangement in advanced primary NSCLC and associated metastases and the relationship between ROS1 rearrangement and clinical data was analyzed.
Result:
The positive rate of ROS1 rearrangement on primary tumor was 2.60% (10/384). For those 246 paired cases, the positive rate on primary tumor was 2.85% (7/246), with that of metastases 1.63% (4/246). Among the 246 cases, there was one case whose metastases was positive, primary tumors negative and 4 case whose primary tumor were positive, metastases were negative. Positive rate of ROS1 rearrangement was higher in the primary lesions than metastases. It was of statistical significance between the two groups (χ[2]=52.341, P<0.001). The positive rate of primary tumors could be predicted by metastases (κ=0.536, P<0.001). The sensitivity was 42.86% (3/7) and the specificity was 99.58% (238/239).
Conclusion:
The metastases of NSCLC can predict ROS1 rearrangement of the primary lesions. It can be used as alternative means for metastases to detect ROS1 rearrangement which are not readily available.
